EP4340842
Sótórasíb til notkunar við meðhöndlun á krabbameini
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
17.5.2022EP published:
27.8.2025EP application number:
22729925.2
EP translation filed:
17.11.2025Grant published:
15.12.2025EPO information:
European Patent Register
Max expiry date:
16.5.2042Expiry date:
16.5.2026
Title in English:
SOTORASIB FOR USE IN THE TREATMENT OF CANCERLanguage of the patent:
English
Timeline
Today
17.5.2022EP application
27.8.2025EP Publication
17.11.2025Translation submitted
15.12.2025Registration published
16.5.2026Expires
Owner
Name:
Amgen Inc.Address:
One Amgen Center Drive, Thousand Oaks, California 91320, US
Inventor
Name:
HENARY, HabyAddress:
Thousand Oaks, California 91320-1799, US
Name:
NGARMCHAMNANRITH, GatareeAddress:
Thousand Oaks, California 91320-1799, US
Name:
PARK, JosephAddress:
Thousand Oaks, California 91320-1799, US
Name:
DUTTA, SandeepAddress:
Thousand Oaks, California 91320-1799, US
Name:
FRIBERG, GregoryAddress:
Thousand Oaks, California 91320-1799, US
Name:
HOUK, Brett E.Address:
Thousand Oaks, California 91320-1799, US
Name:
MATHER, OmarAddress:
Thousand Oaks, California 91320-1799, US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
202163190061 PDate:
18.5.2021Country:
US
Classification
Categories:
A61K 31/519, A61P 35/00, A61P 35/04